Your browser doesn't support javascript.
loading
Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report.
Okada, Kohei; Sakakibara, Rie; Honda, Takayuki; Mitsumura, Takahiro; Shibata, Sho; Shirai, Tsuyoshi; Okamoto, Tsukasa; Furusawa, Haruhiko; Tateishi, Tomoya; Miyazaki, Yasunari.
Afiliación
  • Okada K; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Sakakibara R; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Honda T; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Mitsumura T; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Shibata S; Department of Pulmonary Immunotherapeutic, Tokyo Medical and Dental University, Tokyo, Japan.
  • Shirai T; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Okamoto T; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Furusawa H; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Tateishi T; Department of Pulmonary Immunotherapeutic, Tokyo Medical and Dental University, Tokyo, Japan.
  • Miyazaki Y; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Respir Med Case Rep ; 46: 101929, 2023.
Article en En | MEDLINE | ID: mdl-37886215
ABSTRACT
A 74-year-old man was referred to our hospital with an abnormal chest shadow. Computed tomography (CT) revealed a mass in the left upper lobe and interstitial pneumonia (IP). The patient underwent CT-guided needle biopsy and was diagnosed as lung adenocarcinoma with cT2aN1M1a Stage IVA (PUL). The patient was administered 6 cycles of CBDCA + nab-paclitaxel as first-line, 3 cycles of atezolizumab as second-line, and 8 cycles of S-1 as third-line treatment but finally showed tumor progression. Because comprehensive genome profiling test revealed KRAS G12C mutation, sotorasib was initiated as fourth-line treatment and showed tumor regression without exacerbation of pre-existing IP.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Respir Med Case Rep Año: 2023 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Respir Med Case Rep Año: 2023 Tipo del documento: Article País de afiliación: Japón